**AGP: Board Resolution**

On March 19, 2024, Agimexpharm Pharmaceutical Joint Stock Company announced Resolution No. 04/NQ-AGP.HDQT on implementing the plan on share issuance to pay dividends in 2023 as follows:

Article 1: Approve the implementation of the plan on share issuance to pay dividends in 2023 according to the Annual General Mandate 2024 dated March 15, 2024 follows:

1. Share name: Share of Agimexpharm Pharmaceutical Joint Stock Company
2. Share type: Common share
3. Par value: VND 10,000/share;
4. Current charter capital: VND 206,644,530,000
5. Total number of issued shares: 20,664,453 shares.

In which:

Total number of outstanding shares: 20,664,453 shares

Total number of treasury shares: 0 shares

1. Number of shares expected to be issued: 2,479,734 shares
2. Total issuance value per par value: VND 24,797,340,000
3. Issuance object: Existing shareholders named in the list of shareholders at the record date. The General Meeting of Shareholders authorizes the Board of Directors to decide the record date for the list of shareholders
4. Rate of number of issued shares (The number of shares expected to be issued/Total number of outstanding shares): 12%
5. Rights exercise rate: 100:12, shareholders who own 01 share will have 01 rights to receive additional shares. For every 100 rights to receive additional shares, shareholders will receive 12 new shares.
6. Capital source for the issuance: Undistributed profit after tax. Undistributed profit after tax is determined on December 31, 2023, according to the Audited Financial Statements 2023 of Agimexpharm Pharmaceutical Joint Stock Company
7. Issuance method: Shares issued to existing shareholders will be distributed according to the method of exercising rights.
8. Plan on handling fractional shares: The number of additional shares issued will be rounded down to the number of units, and the decimal fraction (if any) will be removed.

*For example: Shareholder A owns 128 shares at the record date of the list of shareholders. With the exercise rate of 100:12, Shareholder A will receive additionally (128/100\*12) = 15.36 new shares. According to the rounding principle above, shareholder A will receive 15 new shares. The fractional 0.36 shares will be disposed of.*

1. Expected issue date: After the State Security Commission announces that they have received all the reports on the issuance of the Company, expected to implement in Q2, Q3/2024 The General Meeting of Shareholders authorizes the Board of Directors to select a suitable time for the issuance to ensure the rights of shareholders and in compliance with the provision of the law
2. Additional securities and trading registration: The General Meeting of Shareholders approves and authorizes the Board of Directors to implement all the procedures related to additional securities registration at Vietnam Securities Depository and Clearing Corporation and additional trading registration at Hanoi Stock Exchange
3. Approve the change of charter capital: Approve the amendment in the Company’s Charter (the Section on Charter capital) and adjust the Certificate of Business registration at the Department of Planning and Investment of An Giang after the State Security Commission has issued a notice on having received the report on the results of the issuance.

Article 2: The Board of Directors assigns the General Manager of the Company to implement the issuance plan to pay dividends, specifically:

* Carry out the procedures for submitting the dossier for permission to issue shares for dividends payment to the State Securities Commission and explain related issues (when required);
* Prepare and submit the dossiers to the Board of Directors for approval that are related to the Registration of additional securities at the Vietnam Securities Depository and Clearing Corporation and the Registration of additional securities at the Hanoi Stock Exchange after the issuance is approved by the State Securities Commission;
* Carry out the procedures to disclose information following the law;

Article 3: Members of The Board of Directors and Executive Board of Agimexpharm Pharmaceutical Joint Stock Company are responsible for implementing this Resolution.

This Resolution takes effect from the date of its signing.